Daniel K. Treiber
Chief Scientific Officer
Life Science
BioMAP
Japan
Biography
Dr. Daniel K. Treiber is Chief Scientific Officer for Drug Discovery Services. Dr. Treiber co-invented and developed the KINOMEscan® and BROMOscan® screening platforms and InCELL Pulse™ cellular target engagement assay technology. Dr. Treiber has broad expertise in the areas of biochemical and cellular assay technology development and small molecule kinase inhibitor drug discovery and pre-clinical development. Dr. Treiber was previously at Ambit Biosciences where he held leadership positions on multiple kinase-focused drug discovery teams and contributed to the strategic design of quizartinib, a FLT3 kinase inhibitor currently in Phase III studies for the treatment of acute myelogenous leukemia. Dr. Treiber holds several patents and has authored 25 peer-reviewed publications. Dr. Treiber has a Ph.D. from MIT and was a Postdoctoral Fellow at The Scripps Research Institute.
Research Interest
Bioscience
